Cardio-Oncology Research

The Center for Cardiovascular Research at Washington University will combine the efforts of basic, translational, and clinical investigators to examine the subtle cellular changes, biomarkers, and imaging techniques to identify and explain the cardiovascular changes revealed in patients that have received cancer therapies.

  • SURVIVE – cardiovaScUlar toxicity in canceR and improVement In recoVEry
    • Large Multi Center Prospective Clinical Registry for patients with cancer and evidence of cardiovascular disease.
    • All patients that agree to participate in the registry will have blood collected, and possibly saliva samples collected, Quality of Life questionnaires completed, and any standard cardiac imaging will be collated and reviewed by a specialist.
    • Center for Cardiovascular Research scientists will analyze the samples and identify biomarkers that clinicians can use to monitor heart disease while patients are currently being treated for cancer and for a specified time after treatment has been completed.
  • PROTECT PROspecTivE Observation of Cardiac SafeTy with Proteasome Inhibition
    • Large Multi Center Prospective Clinical Registry for patients with cancer and evidence of cardiovascular disease.
    • All patients that agree to participate in the registry will have blood collected, and possibly saliva samples collected, Quality of Life questionnaires completed, and any standard cardiac imaging will be collated and reviewed by a specialist.
    • Center for Cardiovascular Research scientists will analyze the samples and identify biomarkers that clinicians can use to monitor heart disease while patients are currently being treated for cancer and for a specified time after treatment has been completed.
  • PREVENT
    • Primary Objective/Specific Aim #1: to determine if atorvastatin administration preserves LVEF 24 months after the initiation of Anthracycline based chemotherapy for breast cancer or lymphoma. Specific Aim #2: to determine if baseline to 6 month differences in LVEF predict baseline to 24 months differences in LVEF after Anthracycline based chemotherapy and concomitant atorvastatin therapy. This is a double blind, placebo controlled, randomized clinical trial of 0-40 mg of atorvastatin daily in 278 individual scheduled to receive anthracycline based chemotherapy for treatment of stage 1-III breast cancer or lymphoma stage I-OV with a projected >2 year life expectancy. MRI will be used to accurately measure LV function and measurement of biomarkers will be used.
  • THAOS – Transthyretin Amyloidosis Outcomes Survey
    • This is a longitudinal observational study open to all physicians treating all individuals diagnosed or carrying a mutation that puts them at risk for TTR amyloidosis.
  • Amyloidosis Registry
    • This is a retrospective and prospective observational study to understand the physiologic mechanisms contributing to end organ involvement associated with AL and ATTR Amyloidosis. Participants will have blood and possibly tissue/saliva samples collected, and any standard of care imaging will be reviewed by a specialist